Palatin Technologies Inc (Palatin) is focused on developing innovative therapeutics that target the melanocortin receptor (MCR) system. The melanocortin receptor system plays a crucial role in various physiological functions, including inflammation, immune response, food intake, metabolism, and sexual function. The company is exploring all five melanocortin receptors (MC1R through MC5R) to design targeted, receptor-specific therapies. Palatin's research emphasizes the development of agonists, which activate receptor functions, and antagonists, which inhibit them, to achieve substantial pharmacological effects. Palatin’s major focus areas include obesity and male sexual dysfunction.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Palatin focuses on developing first-in-class medicines that modulate the activity of the melanocortin receptor systems. The company's primary R&D initiatives include the development of selective MC4R agonists for obesity therapies targeting rare MC4R pathway disorders such as hypothalamic obesity (HO), Prader-Willi syndrome (PWS), and Bardet-Biedl syndrome (BBS). Additionally, the company is involved in developing melanocortin receptor agonists for ocular diseases, inflammatory and autoimmune diseases, and other rare indications. The company employs an integrated drug design and development approach, utilizing rational and computer-aided drug design, medicinal chemistry, and AI/ML-based computational modeling. The R&D activities of Palatin are primarily managed by a team of 16 full-time employees engaged in research and development. The unit is responsible for discovering and optimizing proprietary peptide, peptide mimetic, and small molecule compounds that modulate the melanocortin receptor system. The unit integrates various scientific disciplines to optimize compounds for receptor selectivity, pharmacokinetic and pharmacodynamic properties, and other characteristics relevant to therapeutic applications. Palatin owns five issued patents in the United States and has issued patents in several other countries, including Australia, Belgium, Brazil, Canada, China, France, Germany, Ireland, Israel, Japan, Korea, Mexico, New Zealand, Russia, South Africa, Sweden, Switzerland, and the UK. The company's pipeline includes multiple products in various stages of development, such as once-weekly peptide MC4R agonists, oral small molecule MC4R agonists, and bremelanotide for obesity. Major technology alliances include collaborations with Boehringer Ingelheim for retinal diseases and Altanispac Labs for dry eye disease. In FY2026, the company spent US$12.3 million on its R&D activities.